J

Johnson & Johnson

Makes prescription drugs and medical devices

Robotics Sales Manager - VELYS-Orthopedics

Full-TimeUpdated on 10/23/2026Deadline 11/6/26
No salary listed
Senior
Bachelor's
Indiana, USA+2 moreMore locations: Michigan, USA | Illinois, USA
RemoteField-based role; travel up to 75% required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree (BA or BS) is required.
  • At least five years of medical device sales experience is required.
  • Experience in joint reconstruction involving hips, knees, or shoulders is required.
  • Ability to travel up to 75% is required.
  • A valid driver's license from one of the 50 states is required.
  • Strong written and verbal communication skills are required.
  • Ability to learn total knee arthroplasty and total hip arthroplasty anatomy and procedures is required.
  • Ability to work autonomously and manage a continuous capital sales pipeline is required.
  • Ability to work within a matrix organization and influence or deliver results without direct authority is required.
  • Ability to lead external engagements, build credibility, and influence surgeons and administrative customers is required.
  • Ability to manage change through Credo leadership behaviors is required.
  • Must adhere to professional, ethical, and compliance standards and support compliance initiatives, programs, training, and activities.
  • Must comply with laws and regulations applicable to DePuy Synthes business activities and the policies and procedures of the Health Care Compliance Program and Johnson & Johnson Business Code of Conduct.
Responsibilities
  • Develop a comprehensive, executable business plan to meet or exceed VELYS sales goals in alignment with the VELYS Digital Surgery Senior Sales Manager team's goals.
  • Lead tactical sales activities to meet or exceed VELYS Digital Surgery Product Portfolio sales goals and desired deal-acquisition target mix ratios.
  • Encourage sales consultant training and host physician familiarization sessions, including dinner programs, case observations, and online training.
  • Work with internal business partners, including HCC, Legal, and Deal Desk, to ensure deal proposals comply with Johnson & Johnson capital sales process requirements.
  • Assist the VELYS Customer Experience Team and Field Sales Organization with customer activities and equipment logistics.
  • Collaborate with adjacent business partners, company support personnel, geographically aligned Strategic Customer Group, and Joint Reconstruction Field Sales personnel to achieve business unit goals.
  • Coordinate with the VELYS Digital Surgery Senior Sales Manager and VELYS Customer Experience Team on launch cadence for VELYS Robotic Assisted Surgery and VELY Hips Navigation units.
  • Work with marketing, professional education, and commercial education teams to advance VELYS Digital Surgery sales and utilization.
  • Manage existing business and new opportunities by understanding the implant and digital surgery business, accelerating deal closure, and forecasting deals accurately.
  • Lead VELYS branding and messaging in the sales territory.
  • Develop customer relationships with clinical and non-clinical stakeholders and expand the customer base in coordination with the VELYS Digital Surgery Senior Sales Manager.
  • Collaborate with the strategic customer group on ASC, large IDNs, Academic Centers, and Joint Reconstruction Field Sales Organization on pipeline opportunities and cross-promotion of the digital surgery product portfolio.
Desired Qualifications
  • Capital sales experience is preferred.
  • Consistent successful sales achievements in previous roles are strongly preferred.
  • Software or digital sales experience is strongly preferred.
  • C-suite and conceptual selling experience is strongly preferred.
  • Experience selling disruptive medical technology is preferred.
  • Previous total joint reconstruction experience is strongly preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.